RxDoctor Payments Data

Sharon Cole, MD

Hematology & Oncology · Findlay, OHNPI 1942293873

Payments from drug & device makers

$12,299in general payments, 2019–2025

Across 823 payments — averaging $14.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$1K
  • Amgen$864
  • Novartis$754
  • Lilly USA, LLC$754
  • Pfizer$698
  • E.r. Squibb & Sons, L.L.C.$615
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$11,02190%
  • Education$1,27710%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astellas Pharma US Inc38$1,013
Amgen74$864
Novartis55$754
Lilly USA, LLC64$754
Pfizer54$698
E.r. Squibb & Sons, L.L.C.55$615
Johnson & Johnson(2 entities)37$610
Genentech USA, Inc.45$562
AstraZeneca(2 entities)36$517
Merck33$484
Pharmacyclics LLC, An Abbvie Company27$483
Seagen Inc.21$428
Incyte Corporation24$403
Bristol Myers Squibb25$297
Takeda Pharmaceuticals U.S.A., Inc.17$265
Gilead(2 entities)13$217
AbbVie12$217
Sanofi12$193
Bayer10$145
Regeneron Healthcare Solutions, Inc.7$143
AMAG Pharmaceuticals, Inc.9$131
Agios Pharmaceuticals, Inc.9$131
Clovis Oncology, Inc.4$130
Servier Pharmaceuticals LLC8$124
Beigene USA, Inc.9$121
Array Biopharma Inc7$118
GSK8$112
Karyopharm Therapeutics Inc.5$111
Tersera Therapeutics LLC6$99
Exelixis Inc.7$96
Daiichi Sankyo Inc.6$94
Ipsen Biopharmaceuticals, Inc5$84
AVEO Pharmaceuticals, Inc.4$80
Boehringer Ingelheim5$78
Puma Biotechnology, Inc.5$73
Blueprint Medicines Corporation5$73
Kyowa Kirin, Inc.5$72
Morphosys, US Inc.4$65
EMD Serono, Inc.5$63
Jazz Pharmaceuticals Inc.4$59
Eisai Inc.3$58
Rigel Pharmaceuticals, Inc.4$54
Mirati Therapeutics, Inc.2$44
Foundation Medicine, Inc.2$43
Fortovia Therapeutics, Inc.4$41
Adaptive Biotechnologies Corporation3$40
Dova Pharmaceuticals2$34
Pharmacosmos Therapeutics Inc.2$34
G1 Therapeutics, Inc.2$34
CTI Biopharma Corp.2$32
Verastem, Inc.2$31
Lexicon Pharmaceuticals, Inc.2$28
Pharmaessentia USA Corporation1$27
Tesaro, Inc.2$27
Tolmar Pharmaceuticals, Inc.2$27
Innate Pharma, Inc1$27
Sun Pharmaceutical Industries Inc.1$21
Dendreon Pharmaceuticals LLC1$20
Taiho Oncology, Inc.1$19
Myovant Sciences Inc.1$18

How this compares

$12,299 in reported general payments places this provider in the 55th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$111,693
Medicare patients
364
Services billed
890

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib78$1,344,317
JakafiRuxolitinib Phosphate39$699,939
CalquenceAcalabrutinib Maleate49$664,407
RevlimidLenalidomide42$652,203
PomalystPomalidomide21$440,516
BrukinsaZanubrutinib30$321,294
LynparzaOlaparib12$100,716
EliquisApixaban72$63,299
CreonLipase/Protease/Amylase11$25,799
Anastrozole163$3,391
Tamoxifen Citrate92$2,283
Acyclovir71$1,754
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen57$1,747
Ondansetron Hcl79$1,112
Prochlorperazine Maleate45$884

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$483$1,344,31778 claims
AstraZenecaCalquence, Lynparza$517$765,12461 claims
Incyte CorporationJakafi$403$699,93939 claims
Bristol Myers SquibbRevlimid$297$652,20342 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$615$440,51621 claims
Beigene USA, Inc.Brukinsa$121$321,29430 claims
PfizerEliquis$698$63,29972 claims
AbbVieCreon$217$25,79911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Findlay

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →